GSK wins positive EMA CHMP opinion for Bexsero booster from age 10
FROM THE WIRE · FINANCE.YAHOO.COM
GSK (LSE:GSK) received a positive opinion from the EMA's CHMP on an updated Bexsero label for adolescents and young adults. The panel backed a single Bexsero booster dose for individuals aged 10 years and older, supported by Phase IIIb trial data. The proposed label change would…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishA positive EMA opinion can extend use of a key GSK vaccine in European markets, an ordinary but supportive development for the stock.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01The EMA CHMP gave a positive opinion on an updated Bexsero label.
- 02The panel backed a single booster dose for individuals aged 10 years and older.
- 03The support is based on Phase IIIb trial data.
- 04The proposed change would extend Bexsero use beyond infancy in key European markets.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets